

Psoriasis and Psoriatic Arthritis

Selected References:

- Bandoli G, et al. 2010 Potentially modifiable risk factors for adverse pregnancy outcomes in women with psoriasis. *Br J Dermatol*; 163(2):334-339.
- Ben-David G, et al. 2008. Pregnancy outcome in women with psoriasis. *J Reprod Med*; 53(3):183-187.
- Berman M, et al. 2018. The effect of pregnancy on disease activity in patients with psoriatic arthritis. *J Rheumatol*; 45(12):1651-1655.
- Bobotsis R, et al. 2016. Psoriasis and adverse pregnancy outcomes: a systematic review of observational studies. *Br J Dermatol*; 175(3):464-472.
- Bröms G, et al. 2018. Effect of maternal psoriasis on pregnancy and birth Outcomes: A population-based cohort study from Denmark and Sweden. *Acta Derm Venereol*; 98(8):728-734.
- Butler DC, et al. 2014. Safety of dermatologic medications in pregnancy and lactation: Part II. Lactation. *J Am Acad Dermatol*; 70(3):417.e1-10; quiz 427.
- Caldarola G, et al. 2017. Untreated psoriasis impairs male fertility: A case-control study. *Dermatology*; 233(2-3):170-174.
- Carman WJ, et al. 2017. Pregnancy and infant outcomes including major congenital malformations among women with chronic inflammatory arthritis or psoriasis, with and without etanercept use. *Pharmacoepidemiol Drug Saf*; 26(9):1109-1118.
- Cohen-Barak E, et al. 2011. Pregnancy outcomes in women with moderate-to-severe psoriasis. *J Eur Acad Dermatol Venereol*; 25(9):1041-1047.
- Eudy AM, et al. 2020. Pregnancy outcomes, fertility, and family planning in with psoriatic arthritis. *Obstet Med*; 13(2):70-75.
- Gladman DD, et al. 2005. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. *Ann Rheum Dis*; 64 Suppl 2:ii14-17.
- Harder E, et al. 2014. No increased risk of fetal death or prolonged time to pregnancy in women with psoriasis. *Invest Dermatol*; 34(6):1747-1749.
- Huerta C, et al. 2007. Incidence and Risk Factors for Psoriasis in the General Population. *Arch Dermatol*; 143(12):1559-1565.
- Johansen CB, et al. 2022. Psoriasis and adverse pregnancy outcomes: A nationwide case-control study in 491,274 women in Denmark. *JAAD Int* 7: 146-155.
- Kerola AM, et al. 2024. Patterns of reproductive health in inflammatory rheumatic diseases and other immune-mediated diseases: a nationwide registry study. *Rheumatology (Oxford)*. keae122. PMID: 38503536.
- Kimball AE et al. 2021. Pregnancy Outcomes in Women With Moderate-to-Severe Psoriasis From the Psoriasis Longitudinal Assessment and Registry (PSOLAR) *JAMA Dermatol*; 157(3): 1-6.
- Meissner Y, et al. 2021. Pregnancy in women with psoriatic arthritis: A systematic literature review of disease activity and adverse pregnancy outcomes. *Semin Arthritis Rheum*; 51(3):530-538.
- Meserve J, et al. 2021. Paternal Exposure to Immunosuppressive and/or Biologic Agents and Birth Outcomes in Patients with Immune-Mediated Inflammatory Diseases. *Gastroenterology*; 161(1):107-115.
- Lima XT, et al. 2012. The impact of psoriasis on pregnancy outcomes. *J Invest Dermatol*; 132(1):85-91.
- McMullan P, et al. 2024. Safety of dermatologic medications in pregnancy and lactation: An Update – Part I: Pregnancy. *J Am Acad Dermatol*; S0190-9622(24)00109-9.
- Murase JE, et al. 2005. Hormonal effect on psoriasis in pregnancy & post-partum. *Arch Dermatol*; 141(5):601-606.
- Murase JE, et al. 2014. Safety of dermatologic medications in pregnancy and lactation: Part I. Pregnancy. *J Am Acad Dermatol*; 70(3):401.e1-14.

- Ostensen M. 1992. The effect of pregnancy on ankylosing spondylitis, psoriatic arthritis, and juvenile rheumatoid arthritis. *Am J Reprod Immunol*; 28(3-4):235-237.
- Polachek A, et al. 2018. Outcome of pregnancy in women with psoriatic arthritis compared to healthy controls. *Clinic Rheum*; 38: 895-902.
- Rademaker M, et al. 2018. Psoriasis in those planning a family, pregnant or breast-feeding. The Australasian Psoriasis Collaboration. *Australas J Dermatol*; 59(2):86-100.
- Rahmati S, et al. 2023. Impact of maternal psoriasis on adverse maternal and neonatal outcomes: a systematic review and meta-analysis. *BMC Pregnancy Childbirth*; 23(1):703.
- Raychaudhuri SP, et al. 2003. Clinical course of psoriasis during pregnancy. *Int J Dermatol*; 42(7):518-20.
- Remaeus K, et al. 2019. Maternal and infant pregnancy outcomes in women with psoriatic arthritis: a Swedish nationwide cohort study. *BJOG*; 126(10):1213-1222.
- Secher AEP, et al. 2025. Preterm birth in women with psoriatic arthritis: what are the risks and risk factors? A collaborative cohort study from Sweden, Denmark and Norway. *RMD Open*; 11(4):e005614.
- Seeger JD, et al. 2007. Pregnancy and pregnancy outcome among women with inflammatory skin diseases. *Dermatol*; 214(1):32-39.
- Smith C, et al. 2020. Birth outcomes and disease activity during pregnancy in a prospective cohort of women with psoriatic arthritis and ankylosing spondylitis. *Amer Col Rheum*; 72(7):1029-1037
- Tuğrul Ayanoğlu B, et al. 2018. Diminished ovarian reserve in patients with psoriasis. *Taiwan J Obstet Gynecol*; 57(2):227-230.
- Ursin K, et al. 2018. Disease activity of psoriatic arthritis during and after pregnancy: A prospective multicenter study. *Arthritis Care Res (Hoboken)*; 71(8):1092-1100.
- Yaghi M, et al. 2024. Safety of Dermatologic Medications in Pregnancy and Lactation: An Update – Part II: Lactation. *J Am Acad Dermatol*; S0190-9622(24)00110-5.
- Yang YW, et al. 2011. Psoriasis and pregnancy outcomes: a nationwide population-based study. *J Am Acad Dermatol*; 64(1):71-77.
- Yiu ZZ, et al. 2014. Safety of biological therapies for psoriasis: effects on reproductive potential and outcomes in male and female patients. *Br J Dermatol*; 171(3):485-491.
- Yiu ZZ, et al. 2015. Safety of conventional systemic therapies for psoriasis on reproductive potential and outcomes. *J Dermatolog Treat*; 30:1-6.

Des questions? Appelez le 866.626.6847 | Envoyez un SMS au 855.999.3525 | Envoyez un e-mail ou discutez sur [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, 1 mars 2026.

Psoriasis and Psoriatic Arthritis

Selected References:

- Coppola D, et al. 2007. Evaluating the postmarketing experience of risperidone use during pregnancy: pregnancy and neonatal outcomes. *Drug Saf*; 30(3):247-264.
- Cho H, et al. 2025. Antipsychotic use during pregnancy and outcomes in pregnant individuals and newborns. *J Affect Disord*; 373:495-504.
- Damkier P and Videbech P. 2018. The Safety of Second-Generation Antipsychotics During Pregnancy: A Clinically Focused Review. *CNS Drugs*; 32:351-366.
- Eberhard J., et al. 2007. Prolactin level during 5 years of risperidone treatment in patients with psychotic disorders. *Acta Psychiatrica Scandinavica*; 115(4), 268-276.
- Ennis ZN and Damkier P. 2014. Pregnancy Exposure to Olanzapine, Quetiapine, Risperidone, Aripiprazole and Risk of Congenital Malformation. A Systemic Review. *Basic & Clinical Pharmacology & Toxicology*; 116:315-320.
- Elstein Y, et al. 2004. Pregnancies in Gaucher disease: a 5 -year study. *Am J Obstet Gynecol*; 190:435-441.
- Habermann F, et al. 2013. Atypical Antipsychotic Drugs and Pregnancy Outcome: A Prospective, Cohort Study. *J Clin Psychopharmacol*; 33:453-462.
- Huybrechts KF, et al. 2016. Antipsychotic Use in Pregnancy and the Risk for Congenital Malformations. *JAMA Psychiatry*; 73(9): 938-946.
- National Library of Medicine. 2026. Drug labeling information (section 8.2). DailyMed. <https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a6767972-2d3f-482b-80bd-ac93e28fdd05&type=display#section-8.2>
- McAllister-Williams RH, et al. 2017. British Association for Psychopharmacology consensus guidance on the use of psychotropic medication preconception, in pregnancy and postpartum 2017. *J Psychopharmacol*; 31(5): 519-552.
- Park Y, et al. 2018. Continuation of Atypical Antipsychotic Medication During Early Pregnancy and the Risk of Gestational Diabetes. *Am J Psychiatry*; 175(6):564-574.
- Petersen I, et al. 2016. Risks and Benefits of Psychotropic Medication in Pregnancy: Cohort Studies based on UK Electronic Primary Care Health Records. *Health Technol Assess*; 20:1-176
- Straub L, et al. 2022. Association of antipsychotic drug exposure in pregnancy with risk of neurodevelopmental disorders: a national birth cohort study. *JAMA Intern Med*; 182(5):522-533.
- Uguz F. 2016. Second-Generation Antipsychotics During the Lactation Period. *J Clin Psychopharmacol*; 36(3):244-252.
- Uguz F. 2019. Adverse events in a breastfed infant exposed to risperidone and haloperidol. *Breastfeed Med*; 14:683-684.
- Vigod SN, et al. 2015. Antipsychotic Drug Use In Pregnancy: High Dimensional, Propensity Matched, Population Based Cohort Study. *BMJ*; 350:h2298.
- Wang E, et al. 2025. Comparative safety of antipsychotic medications and mood stabilizers during pregnancy: A systematic review and network meta-analysis of congenital malformations and prenatal outcomes. *CNS Drugs*; 39(1):1-22.

Des questions? Appelez le 866.626.6847 | Envoyez un SMS au 855.999.3525 | Envoyez un e-mail ou discutez sur [MotherToBaby.org](https://www.mothertobaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, 1 mars 2026.

Psoriasis and Psoriatic Arthritis

Selected References:

- ACOG Committee Opinion No 804. 2020. Physical Activity and Exercise During Pregnancy and the Postpartum Period. *Obstet Gynecol*; 135(4):e178-188.
- ACOG. 2022. Exercise During Pregnancy. Frequently asked questions. Available at: <https://www.acog.org/womens-health/faqs/exercise-during-pregnancy> [Accessed 3/2026].
- Artal R. 2016. Exercise in Pregnancy: Guidelines. *Clin Obstet Gynecol*. 59(3):639-644.
- Barakat R, Perales M. 2016. Resistance Exercise in Pregnancy and Outcome. *Clin Obstet Gynecol*. 59(3):591-599.
- Claiborne, A, et al. 2023. A narrative review of exercise dose during pregnancy. *Birth Defects Res*. 115(17):1581-1597.
- Clapp III JF, et al. 1999. Neonatal behavioral profile of the offspring of women who continued to exercise regularly throughout pregnancy. *Am J Obstet Gynecol*. 180(1):91-94.
- Clapp III JF, et al. 2002. Continuing regular exercise during pregnancy: Effect of exercise volume on fetoplacental growth. *Am J Obstet Gynecol*. 186(1):142-147.
- Cordero Y, et al. 2015. Exercise is associated with a reduction in gestational diabetes mellitus. *Med Sci Sports Exerc*. 47(7):1328-1333.
- Fly AD, et al. 1998. Major mineral concentrations in human milk do not change after maximal exercise testing. *Am J Clin Nutr*. 68(2):345-349.
- Kennelly MM, et al. 2002. Exercise-related changes in umbilical and uterine artery waveforms as assessed by Doppler ultrasound scans. *Am J Obstet Gynecol*. 187(3):661-666.
- Kennelly MM, et al. 2002. Fetal heart rate response to strenuous maternal exercise: not a predictor of fetal distress. *Am J Obstet Gynecol*. 187(3):811-816.
- Kołomańska-Bogucka D, Mazur-Biały AI. 2019. Physical Activity and the Occurrence of Postnatal Depression-A Systematic Review. *Medicina (Kaunas)*. 55(9):560.
- Lederman SA, et al. 1999. Maternal body fat and water during pregnancy: Do they raise infant birth weight? *Am J Obstet Gynecol*; 180(1):235-240.
- Gascoigne EL, et al. 2023. Physical activity and pregnancy outcomes: an expert review. *Am J Obstet Gynecol MFM*; 5(1):100758.

- Gavard J & Artal R. 2008. Effect of Exercise on Pregnancy Outcome. *Clin Obstet Gynecol*; 51(2):467-480.
- Gregg VH & Ferguson JE. 2017. Exercise in Pregnancy. *Clin Sports Med*; 36(4):741-752.
- Greydanus DE & Patel DR. 2002. The female athlete. Before and beyond puberty. *Pediatr Clin North Am*. 49(3):553-580.
- Hicks LE, et al. 2025. Prenatal exercise and its effects on postpartum mental health: systematic review and meta-analysis. *Arch Womens Ment Health*. 28(3):515-524.
- Madsen M, et al. 2007. Leisure time physical exercise during pregnancy and the risk of miscarriage: a study within the Danish National Birth Cohort. *BJOG*; 114(11):1419-1426.
- McLachlan ML, et al. 2026. Case Report: Hyperlactation and Sport Performance in an Elite Marathon Runner. *Clin J Sport Med*. Jan 22. doi: 10.1097/JSM.0000000000001399. Online ahead of print.
- Minguez-Alarcon L, et al. 2014. Physical activity is not related to semen quality in young healthy men. *Fertil Steril*. 102(4): 1103-1109.
- Moolyk AN, et al. 2025. Maternal and fetal responses to acute high-intensity resistance exercise during pregnancy. *Br J Sports Med*. 59(3):159-166.
- Mottola MF, et al. 2018. No. 367-2019. Canadian Guideline for Physical Activity throughout Pregnancy. *J Obstet Gynaecol Can*; 40(11):1528-1537.
- Mussawar M, et al. 2023. The effect of physical activity on fertility: a mini-review. *F S Rep*; 4(2):150-158.
- Oxnard KL, et al. 2026. Patterns in exercise behaviour across pregnancy: a retrospective cohort study of physically active individuals from pre-conception to postpartum. *Eur J Appl Physiol*. Feb 25. doi: 10.1007/s00421-026-06160-6. Online ahead of print.
- Prevett C, et al. 2025. Resistance training in pregnancy: systematic review and meta-analysis of pregnancy, delivery, fetal and pelvic floor outcomes and call to action. *Br J Sports Med*. 59(16):1173-1182.
- Price BB, et al. 2012. Exercise in pregnancy: effect on fitness and obstetric outcomes-a randomized trial. *Med Sci Sports Exerc*; 44(12):2263-2269.
- Redondo-Delgado P, et al. 2025. Effects of strength training on quality of life in pregnant women: A systematic review. *Acta Obstet Gynecol Scand*. 104(7):1231-1243.
- Saccone G, et al. 2026. Exercise in Pregnancy and Risk of Postpartum Depression: A Randomised Controlled Trial. *BJOG*. 133(2):211-217.
- Sanabria-Martínez G, et al. 2019. Effects of physical exercise during pregnancy on mothers' and neonates' health: a protocol for an umbrella review of systematic reviews and metaanalysis of randomised controlled trials. *BMJ Open*; 9(9):e030162.
- Sobal J & Marquart LF. 1994. Vitamin/mineral supplement use among athletes: a review of literature. *Int J Sport Nutr*; 4(4):320-334.
- Suján MJ, et al. 2025. Time restricted eating and exercise training before and during pregnancy for people with increased risk of gestational diabetes: single centre randomised controlled trial (BEFORE THE BEGINNING). *BMJ*. 390:e083398.
- Stafne SN, Salvesen et al. 2012. Regular exercise during pregnancy to prevent gestational diabetes: a randomized controlled trial. *Obstet Gynecol*. 119(1):29-36.
- Tomic V, et al. 2013. The effect of maternal exercise during pregnancy on abnormal fetal growth. *Croat Med J*. 54(4):362-368.
- U.S. Department of Health and Human Services. 2018. Physical activity guidelines for Americans. 2nd ed. Washington, DC: DHHS. Available at: <https://health.gov/paguidelines/second-edition/>. [Accessed March 2026].
- Zouradani A, et al. 2015. The effect of physical exercise on postpartum fitness hormone and lipid levels: a randomized controlled trial in primiparous, lactating women. *Arch Gynecol Obstet* 291(3): 525-530.

Des questions? Appelez le 866.626.6847 | Envoyez un SMS au 855.999.3525 | Envoyez un e-mail ou discutez sur MotherToBaby.org.

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, 1 mars 2026.

Psoriasis and Psoriatic Arthritis

Selected References:

- Ambresin G, et al. 2004. Olanzapine excretion into breast milk: a case report. *J Clin Psychopharmacol*; 24(1):93-95.
- Aydin B, et al. 2015. Olanzapine and quetiapine use during breastfeeding: Excretion into breast milk and safe breastfeeding strategy. *J Clin Psychopharmacol*; 35:206-208.
- Betcher HK, et. al 2020. Psychotropic Treatment During Pregnancy: Research Synthesis and Clinical Care Principles. *J Womens Health* 29(3):310-318.
- Brunner E, et al. 2013. Olanzapine in pregnancy and breastfeeding: a review of data from global safety surveillance. *BMC Pharmacology & Toxicology*, 14, 1-8.
- Croke S, et al. 2003. Olanzapine excretion in human breast milk: estimation of infant exposure. *Int J Neuropsychopharmacol*; 5:243-247.
- Damkier P, et al. 2018. The safety of second-generation antipsychotics during pregnancy: a clinically-focused review. *CNS Drugs* 32:351-366.
- Einarson A & Boskovic R. 2009. Use and safety of antipsychotics during pregnancy. *Journal of Psychiatric Practice*; 15, 183-192.
- Eli Lilly and Company. 2025. Zyprexa product label. Available at: <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d5051fbc-846b-4946-82df-341fb1216341>. Accessed 31 March 2026.
- Ellfolk M, et al. 2021. Second-generation antipsychotic use during pregnancy and risk of congenital malformations. *Eur J Clin Pharmacol*. 2021; 77(11): 1737-1745.
- Ennis ZN, et al. 2014. Pregnancy exposure to Olanzapine, quetiapine, risperidone, aripiprazole and risk of congenital malformations: A systemic review. *Basic & Clinical Pharmacology & Toxicology*; 116(4), 315-320.
- Friedman SH, et al. 2017. Atypical antipsychotic use and outcomes in an urban maternal mental health service. *Int J Psychiatry Med*; 51(6): 521-533.
- Gilad O, et al. 2011. Outcome of infants exposed to olanzapine during breastfeeding. *Breastfeeding Medicine*; 6, 55-58.
- Habermann F, et al. 2013. Atypical antipsychotic drugs and pregnancy outcome: a prospective, cohort study. *J Clin Psychopharmacol*; 33(4):453-462.

- Heinonen E, et al. 2022. Antipsychotic Use During Pregnancy and Risk for Gestational Diabetes: A National Register-Based Cohort Study in Sweden. *CNS Drugs*; 36:529-539.
- Huybrechts KF, et al. 2016. Antipsychotic use in pregnancy and the risk for congenital malformations. *JAMA Psychiatr*; 73(9):938-946.
- Johnson KC et al. 2012. Prenatal antipsychotic exposure and neuromotor performance during infancy. *Arch Gen Psychiatry*; 69(8):787-794. Kallen B, et al. 2013. The use of central nervous system active drugs during pregnancy. *Pharmaceuticals*. 6(10): 1221-1286.
- Kolli P, et al. 2023. Olanzapine Pharmacokinetics: A Clinical Review of Current Insights and Remaining Questions. *Pharmgenomics Pers Med*; 16:1097-1108.
- Manouilenko I, et al. 2018. Long-acting olanzapine injection during pregnancy and breastfeeding: a case report. *Arch Womens Ment Health*; 21(5):587-589
- McKenna K, et al. 2005. Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study. *Journal of Clinical Psychiatry*; 4, 444-449.
- Miller DE, Sebastian CS. 2005. Olanzapine-induced hyperprolactinemia and galactorrhea reversed with addition of bromocriptine: a case report. *J Clin Psychiatr*; 66:269-270.
- Newport DJ, et al 2007. Atypical antipsychotic administration during late pregnancy: placental passage and obstetrical outcomes. *Am J Psychiatry*; 164(8):1214-20.
- Pacchiarotti I, et al. 2016. Mood stabilizers and antipsychotics during breastfeeding: Focus on bipolar disorder. *Eur Neuropsychopharmacol*; 26:1562-1578.
- Park Y, et al. 2018. Continuation of atypical antipsychotic medication during early pregnancy and the risk of gestational diabetes. *Psychiatry*; 175(6):564-574.
- Reutfors J, et al. 2020 Antipsychotic drug use in pregnancy: A multinational study from 10 countries. *Schizophr Res*; 220:106-115.
- Rubakowski J, et al. 2019. Recommendations of the Poliksh Psychiatric Association regarding the treatment of affective disorders in women of childbearing age. Part II: Bipolar disorder. *Psychiatr Pol*; 53(2):263-276.
- Shao P, et al. 2015. Effects of Clozapine and other Atypical Antipsychotics on Infants Development Who Were Exposed to as Fetus: A Post-Hoc Analysis. *PLoS One*; 10(4).
- Teodorescu A, et al. 2017. Dilemma of treating schizophrenia during pregnancy: a case series and a review of literature. *BMC Psychiatry*; 17(1):311.
- Vigod SN, et al. 2015. Antipsychotic drug use in pregnancy: high dimensional, propensity matched, population based cohort study. *BMJ*; 350:h2298.

Des questions? Appelez le 866.626.6847 | Envoyez un SMS au 855.999.3525 | Envoyez un e-mail ou discutez sur [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, 1 mars 2026.

Psoriasis and Psoriatic Arthritis

Selected References:

- Aljazaf K, et al. 2003. Pseudoephedrine: effects on milk production in women and estimation of infant exposure via breastmilk. *Br J Clin Pharmacol*; 56(1):18- 24.
- Anastasio GD, et al. 1992. Fetal tachycardia associated with maternal use of pseudoephedrine, an over-the-counter oral decongestant. *J Am Board Fam Pract*; 5(5):527-528.
- Dor S, et al. 2025. Exposure to pseudoephedrine during pregnancy and major congenital malformations: Findings from a large population-based cohort of pregnancies. *Br J Clin Pharmacol*; 91(6):1834-1841.
- Eglash A. 2014. Treatment of maternal hypergalactia. *Breastfeed Med*; 9:423-425.
- Findlay JW, et al. 1984. Pseudoephedrine and triprolidine in plasma and breast milk of nursing mothers. *Br J Clin Pharmacol*; 18(6):901-906.
- Głowacka K, et al. 2021. Pseudoephedrine-Benefits and Risks. *Int J Mol Sci*; 22(10):5146.
- Heinonen OP, et al. 1977. *Birth Defects and Drugs in Pregnancy*. Littleton, MA: John Wright-PSG. pp 345-356.
- Ito S, et al. 1993. Prospective follow-up of adverse reactions in breast-fed infants exposed to maternal medication. *Am J Obstet Gynecol*; 168(5):1393-1399.
- Miller RK. 1992. From the pages of Teratology: vitamin A to pseudoephedrine issues in patient counseling. *Teratology*; 45(4):341-343.
- Pseudoephedrine Drug Label. 2022. <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1056d9da-8a3f-4b7a-878e-7f8d45d298cd&audience=consumer>. Accessed 24 March 2026.
- Rosa F. 1993. Personal communication. Cited in: Briggs GG, et al. 2005. *Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk*. Seventh Edition. Baltimore, MD: Williams & Wilkins.
- Schatz M, et al. 1997. Asthma and allergy in pregnancy. *Clin Perinatol*; 24(2):407-432.
- Smith CV, et al. 1990. Effect of a single dose of oral pseudoephedrine on uterine and fetal Doppler blood flow. *Obstet Gynecol*; 76(5 Pt 1):803-806.
- Smith J, et al. 1994. *Drugs of choice for pregnant women*. In: Koren G. *Maternal-fetal Toxicology. A Clinician's Guide*. 1994. Second Edition. New York NY: Marcel Dekker Inc.
- Soussan C, et al. 2014. Drug-induced adverse reactions via breastfeeding: a descriptive study in the French Pharmacovigilance Database. *Eur J Clin Pharmacol*; 70:1361-1366.
- The American College of Obstetricians and Gynecologists (ACOG). 2025. "Ask ACOG: What medicine can I take for allergies while I'm pregnant?" Available at: <https://www.acog.org/womens-health/experts-and-stories/ask-acog/what-medicine-can-i-take-for-allergies-while-im-pregnant>. Accessed 24 March 2026.
- The American College of Obstetricians and Gynecologists (ACOG) and The American College of Allergy, Asthma and Immunology (ACAAI). 2000. The use of newer asthma and allergy medications during pregnancy. *Ann Allergy Asthma Immunol*; 84(5):475-480.
- Torfs CP, et al. 1996. Maternal medications and environmental exposures as risk factors for gastroschisis. *Teratology* 54(2):84-92.
- Yau W-P, et al. 2013. Use of decongestants during pregnancy and the risk of birth defects. *Am J Epidemiol*; 178(2):198-208.
- Werler MM, et al. 2003. Association of vasoconstrictive exposures with risks of gastroschisis and small intestinal atresia. *Epidemiology*; 14(3):349-354.

- Werler MM, et al. 1992. First trimester maternal medication use in relation to gastroschisis. *Teratology*; 45(4):361-367.
- Werler MM, et al. 2002. Maternal medication use and risks of gastroschisis and small intestinal atresia. *Am J Epidemiol*; 155(1):26-31.
- Werler MM, et al. 2004. Vasoactive exposures, vascular events, and hemifacial microsomia. *Birth Defects Res A Clin Mol Teratol*; 70(6):389-395.

Des questions? Appelez le 866.626.6847 | Envoyez un SMS au 855.999.3525 | Envoyez un e-mail ou discutez sur [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, 1 mars 2026.